



Resolution n°16-2020-e

Unitaid support to the Medicines Patent Pool Foundation during Phase III (2021-2025)

Recalling that in 2010, Unitaid established the Medicines Patent Pool Foundation (“the Foundation”) as an independent Swiss Foundation and has since successfully supported the Foundation on a continuing basis through Phases I and II of its implementation;

Acknowledging the alignment of the Foundation’s Phase III proposal, entitled ‘*Improving quality of life by expanding access to quality, appropriate, affordable, safe and effective essential medicines and technologies in low- and middle-income countries*’ (“the Phase III Plan”), with Unitaid’s own mandate and Strategy; and

Taking into account the assessment by the PRC and the Secretariat’s recommendations, the Board hereby authorizes, subject to the availability of funds, the Executive Director to commit an additional amount of up to US\$ 34,270,691 for the implementation of the Phase III Plan by the Foundation during the five year period from 1 January 2021 (“the Phase III Term”), subject to the conclusion of a legal agreement between the Foundation and Unitaid.

The Board acknowledges that, during the Phase III Term, Unitaid may receive funding earmarked for the Foundation from third party donors seeking to fund the implementation by the Foundation of activities either within or outside the scope of the Phase III Plan (“Additional Funding”) and notes that such donors shall not be permitted to amend the scope of the Phase III Plan;

The Board hereby authorizes the Executive Director to transfer any Additional Funding received during the Phase III Term to the Foundation, subject to compliance with any requirements of WHO, together with the conclusion of an appropriate legal instrument between Unitaid and the Foundation establishing the terms for the fund transfer, including the Foundation’s agreement to the original donor’s ear-marking conditions.

In the event that Additional Funding is accepted by either Unitaid or the Foundation for activities within the scope of the Phase III Plan, the Board authorises the Secretariat to reduce Unitaid’s funding commitment approved through this decision by decommitting up to the amount of the new funds.

Lead Organization: Medicines Patent Pool Foundation

Phase III Term: 5 years from 1 January 2021 to 31 December 2025

Marisol Touraine
Chair of the Unitaid Executive Board

Date: 11 November 2020